AngioDynamics Appoints Shawn McCarthy Senior Vice President and General Manager of Its Peripheral Vascular Business Unit
"Shawn brings global leadership experiences across critical functions, managing product platforms in multiple companies and countries. He has a track record of successfully commercializing new products in important therapeutic areas, in highly regulated medical device markets," said Mr. Keltjens. "Shawn possesses a deep customer understanding with significant success in marketing and sales. By joining our team he continues to build our capabilities in the marketplace and increase our capacity for future growth."
Mr. McCarthy has more than 18 years of medical device commercial
experience, with his last 10 years being at Johnson & Johnson. He began
his career at Johnson & Johnson in 1998, as a product director for
Cordis Corporation. He has held sales and marketing positions of
increasing responsibility, ultimately leading to his most recent role as
Vice President of Marketing at Cordis for their Endovascular and
Cardiology divisions. Prior to joining Johnson & Johnson, Mr. McCarthy
was the Senior Global Product Manager for the Respiratory Division of
Sunrise Medical, Inc. He received his B.A. and M.B.A. from Syracuse
"I am looking forward to building on our position as the leader in the endovenous laser market, leveraging the strength of our VenaCure EVLT brand, our broader vein interventional business, as well as exciting new therapies such as our Benephit® system for targeted renal drug delivery," said Mr. McCarthy. "We expect to continue advancing our relationships with physicians to deliver the best therapies available for their patients. I am committed to creating value for them, our employees, and our shareholders."
Mr. McCarthy will relocate to upstate New York where he will join AngioDynamics on August 17. He replaces Sean Morris, who has served as SVP and GM of the Peripheral Vascular Unit since June 2008. Mr. Morris has agreed to assist during the transition period and will leave the Company when the transition is complete. "I would like to thank Sean Morris for his important contributions to AngioDynamics during his nine years of service and wish him the very best in the future," said Mr. Keltjens.
AngioDynamics, Inc. ("AngioDynamics" or the "Company") is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company's expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of the Company to integrate purchased businesses as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2008. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
SOURCE: AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
EVC Group, Inc.
Doug Sherk, 415-896-6820
Jenifer Kirtland, 415-896-6820
Chris Gale, 646-201-5431